After the observation of encouraging activity with pertuzumab and trastuzumab combination therapy in patients with HER2-positive MBC who had experienced progression on trastuzumab-based therapy, 18 ...

PURPOSEWe aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzuma ...

Pertuzumab and pertuzumab/trastuzumab in breast cancer: now minor added benefit Advantages in overall survival and recurrence often only become apparent after a longer period of time – current ...

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...

The DESTINY-Breast09 trial randomized 1157 patients with locally advanced or metastatic HER2-positive breast cancer to receive either trastuzumab deruxtecan plus pertuzumab (n = 383), trastuzumab ...

Trastuzumab and pertuzumab are 2 cancer drugs given together. It’s used to treat early, locally advanced and secondary breast cancer that is HER2 positive. You pronounce trastuzumab as ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

-- Phase II Study Evaluating a Novel Targeted Combination Regimen Showed Promising Results in the Neoadjuvant (Pre-surgery) Setting -- SAN ANTONIO, Texas--(BUSINESS WIRE)-- Genentech, a member of the ...

Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients (P < .00001).

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

Sixty-three patients were enrolled in the phase 2 IMMUN-HER study (NCT03144947) evaluating SC (n = 32) vs IV (n = 31) trastuzumab administration.In the IV trastuzumab arm, 20 of 31 patients (64.5% ...

Median duration of follow-up was nearly 2.5 years (29.2 months). As of the data cut-off, 302 (39.6%) patients remained on treatment, 174 in the ENHERTU plus pertuzumab arm and 128 in the THP arm.